Novo Nordisk’s Wegovy pill shattered sales forecasts in its first two weeks, rocketing the company’s stock 7% higher and igniting a frenzy over the future of weight-loss drugs.
Story Highlights
- Wegovy pill launched January 5, 2026, topping 18,000 prescriptions in week one and 26,100 in week two for over 44,000 total.
- Week two sales exceeded Bank of America’s 2,000 weekly target by 1,200%, validating Novo’s 2026 revenue goals instantly.
- Stock surged 7%+ on the news, signaling investor bets on oral GLP-1s grabbing 25% of a $95 billion market by 2030.
- Pill’s explosive uptake outpaces injectable rivals like Eli Lilly’s Zepbound, highlighting patient preference for needle-free options.
- Amid global obesity crisis affecting 1 billion adults, this breakthrough promises easier access to 15-20% weight loss.
Wegovy Pill Launch Triggers Prescription Avalanche
Novo Nordisk launched the Wegovy pill on January 5, 2026, in the U.S. market. IQVIA data shows over 18,000 prescriptions in the first week ending January 11. Week two, January 12-18, delivered 26,100 scripts, totaling more than 44,000.
Bank of America analysts calculated Novo needed about 2,000 weekly prescriptions to meet 2026 sales projections. Week two smashed that benchmark by 1,200%, proving immediate blockbuster potential.
Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance https://t.co/qMopInI5w6
— CNBC International (@CNBCi) May 6, 2026
Stock Surge Reflects Market Validation
News of the prescription surge drove Novo Nordisk’s stock up over 7% on January 19-20, 2026. Investors reacted to the pill’s rapid adoption, contrasting slower ramps for injectables.
Eli Lilly’s Zepbound took a full month to hit 25,000 prescriptions after its 2023 launch. The pill’s convenience—no needles—spurred patient demand, easing prior supply shortages that plagued injectables since 2023.
Semaglutide Evolution from Injections to Pills
Semaglutide powered Novo’s Ozempic for diabetes since the 2000s and injectable Wegovy approved in 2021 for obesity. Clinical trials showed 15-20% body weight loss. Oral semaglutide debuted as Rybelsus for diabetes in 2019.
The Wegovy pill, approved late 2025, targets obesity directly. This form tackles needle aversion and side-effect barriers, aligning with U.S. obesity rates exceeding 36% among adults.
Global obesity now affects over 1 billion adults, with projections hitting 4 billion overweight or obese by 2035 per the World Obesity Federation. Novo dominates the GLP-1 market at 50% diabetes share, ahead of Eli Lilly’s tirzepatide drugs like Mounjaro and Zepbound.
Analyst Upgrades and Competitive Pressures
Bank of America upgraded forecasts based on the pill’s trajectory. Goldman Sachs projects oral GLP-1s capturing 25% of a $95 billion market by 2030. Novo’s CEO Lars Fruergaard Jørgensen oversees production expansions to match demand.
Eli Lilly challenges with injectables, but the pill’s edge suggests a market shift. Recent reports note narrowed 2026 profit guidance to 4-7% due to injectable slowdowns, yet the pill offsets this.
$GDRX Wegovy pill sales smash forecasts, sending Novo Nordisk stock 7% higher
— Shivaprakash Kallasarpe (@kallasarpe21271) May 6, 2026
Wegovy sales history underscores momentum: 2023 at $4.5 billion, 2024 full-year projected $7.8 billion up 73% year-over-year, Q4 hitting record 20 billion DKK.
2025 saw quarterly growth eight times prior levels. The pill positions Wegovy to surpass Ozempic revenue by 2027, peaking before generics in 2028-2029.
Sources:
First GLP-1 weight loss pill sales surge, giving Novo a market bump
Wegovy sales by Novo Nordisk by quarter
FirstWordPharma story on Novo Nordisk
